FibroBiologics, Inc. (FBLG): who owns it and who trades it
As of Nov 16, 2026, FBLG insiders reported 7 purchases worth $120K in the last 12 months. The largest buyer was Ruben A Garcia (General Counsel), with $60.8K.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, FBLG insiders reported $120K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | Hamid Khoja | Chief Scientific Officer | Purchase | 30,000 | $0.38 | $11.4K | Form 4 |
| Mar 4, 2026 | Pete O'Heeron | CEO | Purchase | 15,872 | $0.38 | $6K | Form 4 |
| Mar 3, 2026 | Pete O'Heeron | CEO | Purchase | 18,200 | $0.41 | $7.5K | Form 4 |
| Mar 2, 2026 | Pete O'Heeron | CEO | Purchase | 17,428 | $0.35 | $6.1K | Form 4 |
| Mar 2, 2026 | Jason Davis | CFO | Purchase | 70,000 | $0.41 | $28.7K | Form 4 |
| Feb 27, 2026 | Ruben A Garcia | General Counsel | Purchase | 40,000 | $0.33 | $13.2K | Form 4 |
| Dec 11, 2025 | Ruben A Garcia | General Counsel | Purchase | 140,000 | $0.34 | $47.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ruben A Garcia | General Counsel | $60.8K | – | Feb 27, 2026 |
| Jason Davis | Chief Financial Officer | $28.7K | – | Mar 2, 2026 |
| Pete O'Heeron | CHIEF EXECUTIVE OFFICER, Director | $19.6K | – | Mar 4, 2026 |
| Hamid Khoja | Chief Scientific Officer | $11.4K | – | Mar 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FBLG short interest
Moderate short interest. 5.0% of FBLG shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went up 41%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 334,123 FBLG shares were sold short, 5.0% of the shares outstanding, up 1.1% from the report before. At the average daily volume of 106,998 shares, buying them all back would take about 3.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 334,123 | 5.02% | +1% | 106,998 | 3.1 |
| Oct 15, 2026 | 330,551 | 4.96% | -37% | 140,541 | 2.4 |
| Sep 30, 2026 | 522,114 | 7.84% | -21% | 136,516 | 3.8 |
| Sep 15, 2026 | 661,912 | 9.94% | +60% | 357,923 | 1.9 |
| Aug 31, 2026 | 413,742 | 6.21% | +192% | 294,961 | 1.4 |
| Aug 14, 2026 | 141,714 | 2.13% | +23% | 248,372 | 1.0 |
| Jul 31, 2026 | 115,200 | 1.73% | +63% | 90,907 | 1.3 |
| Jul 15, 2026 | 70,837 | 1.36% | -48% | 59,556 | 1.2 |
| Jun 30, 2026 | 135,794 | 2.61% | -1% | 260,529 | 1.0 |
| Jun 15, 2026 | 137,027 | 2.63% | +1% | 148,389 | 1.0 |
| May 29, 2026 | 135,591 | 2.60% | -43% | 99,753 | 1.4 |
| May 15, 2026 | 237,640 | 4.56% | +101% | 563,635 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
FibroBiologics company events
FibroBiologics filed 24 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing). The latest was on Oct 8, 2026.
- Oct 8, 2026AgreementFibroBiologics, Inc. entered into a securities purchase agreement with Peak One Opportunity Fund, L.P., pursuant to which the Company agreed to issue to Peak One, in a private placement offering upon the satisfaction of certain conditions specified in the SPA, a convertible debenture in the… Filing
- Sep 18, 2026VoteReported shareholder vote results. Filing
- Sep 15, 2026AgreementFibroBiologics, Inc. entered into a securities purchase agreement with Hamid Khoja, Ph.D., the Company’s Chief Scientific Officer, relating to the issuance and sale of 298,508 shares of the Company’s common stock, par value $0.00001 per share, and accompanying warrants to purchase up to 298,508… Filing
- Aug 24, 2026LeadershipThe Board of Directors of FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of the Board, effective August 20, 2026, to serve until the expiration of his term at the 2028 annual meeting of stockholders. Filing
- Jul 24, 2026ListingFibroBiologics, Inc. received a Staff Determination letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that Nasdaq Staff had determined to delist the Company’s securities from The Nasdaq Capital Market. Filing
- Jul 9, 2026LeadershipMatt Link notified FibroBiologics, Inc. that he was resigning from the Board of Directors, effective as of July 2, 2026. Filing
- Jun 29, 2026AgreementFibroBiologics, Inc. entered into a Securities Purchase Agreement with an accredited investor for a private placement offering, pursuant to which the Company received gross proceeds of $3 million, before deducting placement agent fees and other offering expenses, in consideration of (i) pre-funded… Filing
- Jun 23, 2026LeadershipFibroBiologics, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 6, 2026AgreementAs previously disclosed, on May 1, 2026, FibroBiologics, Inc. entered into that certain At The Market Offering Agreement with H.C. Wainwright & Co., LLC under which the Company may issue and sell shares of its common stock, par value $0.00001 per share from time to time through or to the Sales Agent. Filing
- May 5, 2026LeadershipThe Compensation Committee of the Board of Directors of FibroBiologics, Inc. granted, pursuant to the Company’s 2022 Stock Plan, options to purchase 92,410 shares of common stock to Pete O’Heeron, the Company’s’ Chief Executive Officer, and options to purchase 61,607 shares of common stock to each… Filing
- May 1, 2026AgreementFibroBiologics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC under which the Company may issue and sell in a registered offering shares of its common stock, par value $0.00001 per share, having an aggregate offering price of up to $6.15 million from time to… Filing
- Apr 20, 2026AnnouncementThe Company received formal notice from Nasdaq that the Company has demonstrated compliance with the bid price requirement under Nasdaq Listing Rule 5550(a)(2) and all other applicable criteria for continued listing on The Nasdaq Capital Market. Filing
- Apr 17, 2026RulesChanged its bylaws or articles. Filing
- Apr 9, 2026AgreementAmended an earlier report. FibroBiologics, Inc. entered into a Sublease Buyout Agreement with United Fire & Casualty Co. (doing business as United Fire Group) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022, pursuant to which Sublandlord subleased to the Company certain premises… Filing
- Apr 9, 2026AgreementFibroBiologics, Inc. entered into a Sublease Buyout Agreement with United Fire & Casualty Co. (doing business as United Fire Group) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022, pursuant to which Sublandlord subleased to the Company certain premises… Filing
- Apr 3, 2026SharesChanged the rights of its shareholders. Filing
- Apr 2, 2026AgreementFibroBiologics, Inc. commenced a best-efforts public offering of (i) 1,028,788 shares of the Company’s common stock, $0.00001 par value per share, (ii) pre-funded warrants in lieu of Shares to purchase up to 1,243,940 shares of Common Stock, and (iii) warrants to purchase one share of its Common… Filing
- Mar 6, 2026LeadershipThe Compensation Committee of the Board of Directors of FibroBiologics, Inc. approved a new annual base salary of $400,000, effective January 1, 2026, for Jason D. Davis, the Company’s Chief Financial Officer. Filing
- Feb 23, 2026VoteReported shareholder vote results. Filing
- Feb 6, 2026ListingAs previously reported, on August 4, 2025, FibroBiologics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that its market value of listed securities had closed below the minimum $35 million threshold required for continued listing… Filing
- Jan 2, 2026ListingAs previously reported, on July 1, 2025, FibroBiologics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as… Filing
- Dec 15, 2025AgreementFibroBiologics, Inc. entered into a securities purchase agreement with certain institutional investors, pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering, 5,227,275 shares of the Company’s common stock, $0.00001 par value per share. Filing
- Nov 25, 2025AgreementFibroBiologics, Inc. entered into a securities purchase agreement with certain institutional investors, pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering, 4,477,614 shares of the Company’s common stock, $0.00001 par value per share. Filing
- Nov 19, 2025AgreementFibroBiologics, Inc. entered into a securities purchase agreement with a single investor, pursuant to which (i) the Company agreed to issue and sell to the Purchaser, in a registered direct offering, 3,540,000 shares of the Company’s common stock, $0.00001 par value per share and pre-funded… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
FibroBiologics financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named FBLG in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 10.0% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 10.0% |
Questions about FibroBiologics, Inc. (FBLG) stock
Are FBLG insiders buying or selling?
In the last 12 months, FBLG insiders reported 7 open-market purchases worth $120K and no sales. The latest trade was on Mar 4, 2026. See every trade.
What is the short interest in FBLG?
As of Oct 30, 2026, 334,123 FBLG shares were sold short, 5.0% of the shares outstanding, up 1.1% from the report before. At the average daily volume of 106,998 shares, buying them all back would take about 3.1 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.